Bukwang Pharm
Bukwang Pharmaceutical Co., Ltd. develops, produces, and sells pharmaceutical products in South Korea and internationally. It offers its products in oral solid dosage forms, injections, oral solutions, external solutions, and ointments. The company also provides ethical drugs, including drugs for treating diabetic peripheral neuropathy, hypothyroidism, toxic liver disease, chronic hepatitis, live… Read more
Market Cap & Net Worth: Bukwang Pharm (003000)
Bukwang Pharm (KO:003000) has a market capitalization of $409.02 Million (₩598.89 Billion) as of March 18, 2026. Listed on the KO stock exchange, this Korea-based company holds position #11797 globally and #278 in its home market, demonstrating a 22.75% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Bukwang Pharm's stock price ₩6070.00 by its total outstanding shares 98664671 (98.66 Million).
Bukwang Pharm Market Cap History: 2015 to 2026
Bukwang Pharm's market capitalization history from 2015 to 2026. Data shows change from $806.09 Million to $409.02 Million (-4.25% CAGR).
Bukwang Pharm Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Bukwang Pharm's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.00x
Bukwang Pharm's market cap is 0.00 times its annual revenue
1.02x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $806.09 Million | $142.13 Billion | $25.14 Billion | 0.01x | 0.03x |
| 2016 | $1.02 Billion | $138.62 Billion | $15.81 Billion | 0.01x | 0.06x |
| 2017 | $1.02 Billion | $150.74 Billion | $11.09 Billion | 0.01x | 0.09x |
| 2018 | $1.40 Billion | $194.22 Billion | $145.67 Billion | 0.01x | 0.01x |
| 2019 | $859.87 Million | $168.19 Billion | -$7.41 Billion | 0.01x | N/A |
| 2020 | $1.86 Billion | $169.66 Billion | -$7.20 Billion | 0.01x | N/A |
| 2021 | $859.71 Million | $182.49 Billion | -$916.62 Million | 0.00x | N/A |
| 2022 | $589.62 Million | $190.91 Billion | -$2.47 Billion | 0.00x | N/A |
| 2023 | $411.05 Million | $125.93 Billion | -$31.33 Billion | 0.00x | N/A |
| 2024 | $309.30 Million | $160.09 Billion | -$2.64 Billion | 0.00x | N/A |
Competitor Companies of 003000 by Market Capitalization
Companies near Bukwang Pharm in the global market cap rankings as of March 18, 2026.
Key companies related to Bukwang Pharm by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #410 globally with a market cap of $53.52 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #457 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #721 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #410 | Zoetis Inc | NYSE:ZTS | $53.52 Billion | $121.68 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.60 |
| #457 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #721 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Bukwang Pharm Historical Marketcap From 2015 to 2026
Between 2015 and today, Bukwang Pharm's market cap moved from $806.09 Million to $ 409.02 Million, with a yearly change of -4.25%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩409.02 Million | +60.37% |
| 2025 | ₩255.05 Million | -17.54% |
| 2024 | ₩309.30 Million | -24.75% |
| 2023 | ₩411.05 Million | -30.29% |
| 2022 | ₩589.62 Million | -31.42% |
| 2021 | ₩859.71 Million | -53.74% |
| 2020 | ₩1.86 Billion | +116.15% |
| 2019 | ₩859.87 Million | -38.42% |
| 2018 | ₩1.40 Billion | +37.57% |
| 2017 | ₩1.02 Billion | -0.80% |
| 2016 | ₩1.02 Billion | +26.94% |
| 2015 | ₩806.09 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Bukwang Pharm was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $409.02 Million USD |
| MoneyControl | $409.02 Million USD |
| MarketWatch | $409.02 Million USD |
| marketcap.company | $409.02 Million USD |
| Reuters | $409.02 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.